FIA
CYT

FNY Investment Advisers’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

FNY Investment Advisers’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,297
Closed -$13K – 798
2023
Q2 		$13K Buy
+5,297
New +$11.1K 0.02% 287

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
VAS
VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.46% 1-Year Est. Return

FNY Investment Advisers's CYT Position: Q3 2023 in Review

FNY Investment Advisers sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2023, closing a stake of 5,297 shares — an estimated $13K sold.

FNY Investment Advisers first reported a position in CYT in Q2 2023 and held it in 1 quarter. The position peaked at $13K in Q2 2023. 41 funds tracked by Wall St. Rank hold CYT as of Q3 2023.

  • FNY Investment Advisers reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 5,297 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $13K.
  • FNY Investment Advisers first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • FNY Investment Advisers's Cyteir Therapeutics, Inc. Common Stock position peaked at $13K in Q2 2023.
  • 41 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2023.

Based on FNY Investment Advisers's 13F filing for Q3 2023, filed 10 Oct 2023.